Companies › Sichuan Jishengtang Pharmaceutical
2 active drug programs in 2 registered trials: 2 Phase 3; Neurology, Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Wujia Yizhi granules Traditional Chinese medicine formula for treatment of mild-to-moderate Alzheimer's dementi | – | Phase 3 | Alzheimer's Dementia | Dec 2026 |
| Shugan Jieyu Capsules Herbal formulation | – | Phase 3 | Generalized Anxiety Disorder | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05772104 | Shugan Jieyu Capsules | Phase 3 | Generalized Anxiety Disorder | Psychiatry | Feb 2025 |
| NCT06534723 | Wujia Yizhi granules | Phase 3 | Alzheimer's Dementia | Neurology | Dec 2026 |
No annotated target.
–
Impax Laboratories Intra-Cellular Therapies Rapport Therapeutics Lipocine Xenon Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.